Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice

Abstract Understanding the intricate cellular interactions involved in bone restoration is crucial for developing effective strategies to promote bone healing and mitigate conditions such as osteoporosis and fractures. Here, we provide compelling evidence supporting the anabolic effects of a pharmac...

Full description

Saved in:
Bibliographic Details
Main Authors: Yunqing Liu, Mai Nishiura, Mika Fujii, Sumiti Sandhu, Yasutaka Yawaka, Yutaka Yamazaki, Akira Hasebe, Tadahiro Iimura, Sek Won Kong, Ji-Won Lee
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Cell Communication and Signaling
Subjects:
Online Access:https://doi.org/10.1186/s12964-024-01945-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850162535393656832
author Yunqing Liu
Mai Nishiura
Mika Fujii
Sumiti Sandhu
Yasutaka Yawaka
Yutaka Yamazaki
Akira Hasebe
Tadahiro Iimura
Sek Won Kong
Ji-Won Lee
author_facet Yunqing Liu
Mai Nishiura
Mika Fujii
Sumiti Sandhu
Yasutaka Yawaka
Yutaka Yamazaki
Akira Hasebe
Tadahiro Iimura
Sek Won Kong
Ji-Won Lee
author_sort Yunqing Liu
collection DOAJ
description Abstract Understanding the intricate cellular interactions involved in bone restoration is crucial for developing effective strategies to promote bone healing and mitigate conditions such as osteoporosis and fractures. Here, we provide compelling evidence supporting the anabolic effects of a pharmacological Pyk2 inhibitor (Pyk2-Inh) in promoting bone restoration. In vitro, Pyk2 signaling inhibition markedly enhances alkaline phosphatase (ALP) activity, a hallmark of osteoblast differentiation, through activation of canonical Wnt/β-catenin signaling. Notably, analysis of human mesenchymal stem cells through RNA-seq revealed a novel candidate, SCARA5, identified through Pyk2-Inh treatment. We demonstrate that Scara5 plays a crucial role in suppressing the differentiation from stromal cells into adipocytes, and accelerates lineage commitment to osteoblasts, establishing Scara5 as a negative regulator of bone formation. Additionally, Pyk2 inhibition significantly impedes osteoclast differentiation and bone resorption. In a co-culture system comprising osteoblasts and osteoclasts, Pyk2-Inh effectively suppressed osteoclast differentiation, accompanied by a substantial increase in the transcriptional expression of Tnfrsf11b and Csf1 in osteoblasts, highlighting a dual regulatory role in osteoblast-osteoclast crosstalk. In an ovariectomized mouse model of osteoporosis, oral administration of Pyk2-Inh significantly increased bone mass by simultaneously reducing bone resorption, promoting bone formation and decreasing bone marrow fat. These results suggest Pyk2 as a potential therapeutic target for both adipogenesis and osteogenesis in bone marrow. Our findings underscore the importance of Pyk2 signaling inhibition as a key regulator of bone remodeling, offering promising prospects for the development of novel osteoporosis therapies.
format Article
id doaj-art-6067f1f0488844c1883abcaf1a93aaf9
institution OA Journals
issn 1478-811X
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series Cell Communication and Signaling
spelling doaj-art-6067f1f0488844c1883abcaf1a93aaf92025-08-20T02:22:33ZengBMCCell Communication and Signaling1478-811X2024-11-0122111710.1186/s12964-024-01945-8Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized miceYunqing Liu0Mai Nishiura1Mika Fujii2Sumiti Sandhu3Yasutaka Yawaka4Yutaka Yamazaki5Akira Hasebe6Tadahiro Iimura7Sek Won Kong8Ji-Won Lee9Department of Pharmacology, Faculty and Graduate School of Dental Medicine, Hokkaido UniversityDepartment of Pharmacology, Faculty and Graduate School of Dental Medicine, Hokkaido UniversityDepartment of Oral Health Science, Gerodontology, Faculty of Dental Medicine, Hokkaido UniversityComputational Health and Informatics Program, Boston Children’s HospitalDentistry for Children and Disabled Persons, Department of Oral Functional Science, Faculty of Dental Medicine, Hokkaido UniversityDepartment of Oral Health Science, Gerodontology, Faculty of Dental Medicine, Hokkaido UniversityDepartment of Oral Pathobiological Science, Microbiology, Graduate School of Dental Medicine, Hokkaido UniversityDepartment of Pharmacology, Faculty and Graduate School of Dental Medicine, Hokkaido UniversityComputational Health and Informatics Program, Boston Children’s HospitalDepartment of Oral Pathobiological Science, Microbiology, Graduate School of Dental Medicine, Hokkaido UniversityAbstract Understanding the intricate cellular interactions involved in bone restoration is crucial for developing effective strategies to promote bone healing and mitigate conditions such as osteoporosis and fractures. Here, we provide compelling evidence supporting the anabolic effects of a pharmacological Pyk2 inhibitor (Pyk2-Inh) in promoting bone restoration. In vitro, Pyk2 signaling inhibition markedly enhances alkaline phosphatase (ALP) activity, a hallmark of osteoblast differentiation, through activation of canonical Wnt/β-catenin signaling. Notably, analysis of human mesenchymal stem cells through RNA-seq revealed a novel candidate, SCARA5, identified through Pyk2-Inh treatment. We demonstrate that Scara5 plays a crucial role in suppressing the differentiation from stromal cells into adipocytes, and accelerates lineage commitment to osteoblasts, establishing Scara5 as a negative regulator of bone formation. Additionally, Pyk2 inhibition significantly impedes osteoclast differentiation and bone resorption. In a co-culture system comprising osteoblasts and osteoclasts, Pyk2-Inh effectively suppressed osteoclast differentiation, accompanied by a substantial increase in the transcriptional expression of Tnfrsf11b and Csf1 in osteoblasts, highlighting a dual regulatory role in osteoblast-osteoclast crosstalk. In an ovariectomized mouse model of osteoporosis, oral administration of Pyk2-Inh significantly increased bone mass by simultaneously reducing bone resorption, promoting bone formation and decreasing bone marrow fat. These results suggest Pyk2 as a potential therapeutic target for both adipogenesis and osteogenesis in bone marrow. Our findings underscore the importance of Pyk2 signaling inhibition as a key regulator of bone remodeling, offering promising prospects for the development of novel osteoporosis therapies.https://doi.org/10.1186/s12964-024-01945-8Pyk2BoneMesenchymal stem cellOsteoclastOsteoblastAdipocyte
spellingShingle Yunqing Liu
Mai Nishiura
Mika Fujii
Sumiti Sandhu
Yasutaka Yawaka
Yutaka Yamazaki
Akira Hasebe
Tadahiro Iimura
Sek Won Kong
Ji-Won Lee
Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
Cell Communication and Signaling
Pyk2
Bone
Mesenchymal stem cell
Osteoclast
Osteoblast
Adipocyte
title Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
title_full Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
title_fullStr Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
title_full_unstemmed Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
title_short Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice
title_sort selective pyk2 inhibition enhances bone restoration through scara5 mediated bone marrow remodeling in ovariectomized mice
topic Pyk2
Bone
Mesenchymal stem cell
Osteoclast
Osteoblast
Adipocyte
url https://doi.org/10.1186/s12964-024-01945-8
work_keys_str_mv AT yunqingliu selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT mainishiura selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT mikafujii selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT sumitisandhu selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT yasutakayawaka selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT yutakayamazaki selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT akirahasebe selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT tadahiroiimura selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT sekwonkong selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice
AT jiwonlee selectivepyk2inhibitionenhancesbonerestorationthroughscara5mediatedbonemarrowremodelinginovariectomizedmice